Kura Oncology (NASDAQ:KURA) Now Covered by Analysts at JPMorgan Chase & Co.

Posted by Brian Himes on Oct 1st, 2026

JPMorgan Chase & Co. began coverage on shares of Kura Oncology (NASDAQ:KURA – Get Free Report) in a report issued on Thursday, Briefing.com reports. The firm set an “overweight” rating and a $30.00 price target on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 180.11% from the stock’s current price.

A number of other equities research analysts have also recently commented on KURA. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a report on Monday, August 24th. CLSA set a $24.00 price objective on Kura Oncology in a research note on Thursday, June 4th. Sanford C. Bernstein set a $24.00 price objective on Kura Oncology in a research report on Monday, June 15th. Wedbush lifted their target price on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Finally, Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a report on Monday, August 24th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.69.

View Our Latest Stock Report on KURA

Kura Oncology Stock Performance

Shares of KURA opened at $10.71 on Thursday. The company’s 50 day simple moving average is $11.22 and its 200-day simple moving average is $10.17. The firm has a market cap of $952.76 million, a PE ratio of -3.18 and a beta of 0.44. Kura Oncology has a 12-month low of $7.36 and a 12-month high of $13.90. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12.

Kura Oncology (NASDAQ:KURA – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The firm had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. As a group, equities analysts predict that Kura Oncology will post -3.25 EPS for the current year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Teresa Bair sold 31,487 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the transaction, the insider directly owned 195,444 shares in the company, valued at approximately $2,468,457.72. This represents a 13.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Francis Burrows sold 20,726 shares of the stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $10.83, for a total transaction of $224,462.58. Following the completion of the transaction, the insider directly owned 42,327 shares of the company’s stock, valued at approximately $458,401.41. This trade represents a 32.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 153,881 shares of company stock worth $1,708,183. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Kura Oncology during the second quarter worth $115,286,000. Armistice Capital LLC boosted its position in shares of Kura Oncology by 5.7% in the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after buying an additional 264,000 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Kura Oncology in the 2nd quarter worth about $12,735,000. Dimensional Fund Advisors LP grew its stake in Kura Oncology by 32.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after acquiring an additional 348,127 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Kura Oncology in the 2nd quarter valued at about $10,927,000.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.